Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
84 results about "Pharmaceutical care" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
The most well-known definition for pharmaceutical care came from Doug Hepler and Linda Strand in their article ‘Opportunities and responsibilities in pharmaceutical care’ from 1990. This was a landmark paper because it marked the start of the international movement to make pharmaceutical care more visible, and get the term and the type of care implemented in hospital and community pharmacy practice. During the following years both authors worked to make the concept applicable in practice. The definition reads: ‘Pharmaceutical care is the responsible provision of drug therapy for the purpose of achieving definite outcomes that improve the patients’ quality of life’.
Pharmaceutical system in which pharmaceutical care is provided by a remote professional serving multiple pharmacies
InactiveUS6711460B1More accuracyGuaranteed growthFinanceDigital data processing detailsElectronic networkDrugs preparations
A pharmaceutical system and method of operation in which a single remote professional provides pharmaceutical care and oversight of multiple local pharmacies. A control location is connected through an electronic network to one or more individual pharmacies, each of which may be located at a different physical site. Each individual pharmacy includes one or more drug preparation areas, and one or more self-service or staffed customer terminals. A drug preparation area includes a robot, which is adapted to prepare prescriptions or other items, and which is connected by a pneumatic delivery system to one or more customer terminals within the pharmacy.
Owner:DIEBOLD NIXDORF
Pharmaceutical tablet, completely coated, for controlled release of active principles that present problems of bio-availability linked to gastro-intestinal absorption
Described herein is a particular type of pharmaceutical tablet, for oral use, which is formed by one or more layers, and is specifically designed for controlled release of active principles that present problems of bio-availability linked to absorption in the gastro-intestinal tract, and in particular active principles that present an erratic and unpredictable absorption linked to the presence or absence of food at the level of the stomach and / or of the first portion of the small intestine, the said pharmaceutical form being characterized in that it is completely coated with one or more films of a biocompatible and biodegradable polymeric material.
Owner:JAGOTEC AG
System and method of administering a pharmaceutical gas to a patient
ActiveUS7523752B2Tracheal tubesOperating means/releasing devices for valvesControl systemProduct gas
A method and system for delivering a pharmaceutical gas to a patient. The method and system provide a known desired quantity of the pharmaceutical gas to the patient independent of the respiratory pattern of the patient. The preferred pharmaceutical gases are CO and NO, both of which are provided as a concentration in a carrier gas. The gas control system determines the delivery of the pharmaceutical gas to the patient to result in the known desired quantity (e.g. in molecules, milligrams or other quantified units) of the pharmaceutical gas being delivered. Upon completion of that known desired quantity of pharmaceutical gas over a plurality of breaths, the system can either terminate any further delivery of the pharmaceutical gas or can activate an alarm to alert the user that the known quantity has been delivered. The system also has alarm functions to alert the user of possible malfunctions of the system.
Owner:MALLINCKRODT HOSPITAL PRODUCTS IP LTD
Pharmaceutical system in which pharmaceutical care is provided by a remote professional serving multiple pharmacies
InactiveUS7630788B1More accuracyGuaranteed growthFinanceDrug and medicationsElectronic networkDrugs preparations
A pharmaceutical system and method of operation in which a single remote professional provides pharmaceutical care and oversight of multiple local pharmacies. A control location is connected through an electronic network to one or more individual pharmacies, each of which may be located at a different physical site. Each individual pharmacy includes one or more drug preparation areas, and one or more self-service or staffed customer terminals. A drug preparation area includes a robot, which is adapted to prepare prescriptions or other items, and which is connected by a pneumatic delivery system to one or more customer terminals within the pharmacy.
Owner:DIEBOLD NIXDORF
RFID monitoring of drug regimen compliance
Disclosed is an apparatus and system for monitoring drug regimen compliance, the system utilizing a Radio Frequency Identification (RfID) tag affixed to a pharmaceutical agent and a wearable RFID reader that identifies a patient. The RFID tag identifies the pharmaceutical agent and the RFID reader wirelessly communicates with a central monitoring system upon ingestion of the pharmaceutical agent.
Owner:THE RES FOUND OF STATE UNIV OF NEW YORK
Chronically implantable hybrid cannula-microelectrode system for continuous monitoring electrophysiological signals during infusion of a chemical or pharmaceutical agent
InactiveUS20090187159A1Increasing its useful lifespanEfficiently sensedMedical devicesSensorsMultivariate statisticalPharmaceutical care
A device for assessing the effects of diffusible molecules on electrophysiological recordings from multiple neurons allows for the infusion of reagents through a cannula located among an array of microelectrodes. The device can easily be customized to target specific neural structures. It is designed to be chronically implanted so that isolated neural units and local field potentials are recorded over the course of several weeks or months. Multivariate statistical and spectral analysis of electrophysiological signals acquired using this system could quantitatively identify electrical “signatures” of therapeutically useful drugs.
Owner:CALIFORNIA INST OF TECH
Systems and methods for managing patient pharmaceutical care
Systems and methods are described for allowing a pharmacist to practice pharmaceutical care in an accurate and efficient manner. The present invention provides the systems for gathering, organizing, and maintaining the necessary clinical and patient data, and providing pharmacists access thereto, through integrated computer software. The clinical data classifies drugs into therapeutic classes, and for each class there is associated therewith known indications, contra-indications, recommended dosages, known adverse reactions, and drug interactions. A clinical database and a patient database are used. In the clinical database, each drug is assigned a unique identification code including a therapeutic cross reference (TXR). The TXR allows access to information associated with the drug's adverse reactions, and dosage recommendations, and also to disease indications and contra-indications via a link to the ICD-9s (International Classification of Diseases) associated with the diseases. The patient data includes patient diagnosis profiles and allergy profiles.
Owner:CERNER INNOVATION
System and Method for Providing Pharmacy Services
InactiveUS20150261934A1Improves pharmaceutical healthcare serviceReducing medicalData processing applicationsDrug and medicationsDrug interactionDrug dispensing
The comprehensive and controlled web-based system facilitates provision of pharmaceutical care and dispensing of medications to patients. The system includes multiple retail or pharmacy outlets whose prescription filling activities are supervised and verified by pharmacists at remote sites. The supervision includes visual confirmation by images for the prescription and the drug dispensed and systematic provision of information pertaining to drug interactions and instructions with affirmative patient confirmation. The system ensures patient safety and education, prescription accuracy, and reduction of expense while assisting rural or economically challenged areas to retain local access to pharmacy services.
Owner:TELEPHARM
Enhanced bioavailability of nutrients, pharmaceutical agents, and other bioactive substances through laser resonant homogenization or modification of molecular shape or crystalline form
A method for improving the bioavailability of a bioactive substance includes subjecting the bioactive substance to laser radiation. The laser radiation modifies the bioactive substance to thereby modify reactions relating thereto in the body. The method enables reductions in inflammation associated with autoimmune diseases, modification of reaction by-products in the body, increased homogenization and flattening of molecular shape and improved methylation. The improved methylation can be utilized to reduce homocysteine blood levels, and to reduce anxiety, depression, paranoia, hostility, somatization (perception of bodily distress) and obsessive-compulsive symptoms. Enhanced nitric oxide generation from modified L-arginine can be used to reduce systolic and diastolic blood pressure, lower total and LDL cholesterol levels, and improve the ratio of total to HDL cholesterol. Increased depth of penetration of sparse constructive nodes of laser radiation may increase the range of photodynamic therapy applications and a wide range of in vitro and in vivo modifications of molecular shape and activity. Laser acoustic resonance can be utilized to increase the homogeneity of crystals, or favor the generation of novel or preferred crystalline forms.
Owner:OVOKAITYS TODD F +1
Purine derivatives and their pharmaceutical uses
The present invention relates to compounds of formula (I):wherein;R1 represents hydrogen or C1-3alkyl;n is an integer having a value of 1 to 5;X represents O or NH;Y represents C or N;or a pharmaceutically acceptable salt thereof, have been shown to be inducers of human interferon and may possess an improved profile with respect to known inducers of human interferon, for example enhanced potency. The compounds of the invention may therefore be useful in the treatment of various disorders, in particular the treatment of infectious diseases, cancer, allergic diseases and other inflammatory conditions, and their use as vaccine adjuvants.
Owner:GLAXO SMITHKLINE LLC
Method and apparatus for processing pharmaceutical orders to determine whether a buyer of pharmaceuticals qualifies for an "own use" discount
Disclosed is a method and apparatus for processing pharmaceutical orders to determine whether a buyer of pharmaceuticals qualifies for an “own use” discount. “Own use” discounts on pharmaceuticals are available for a limited class of buyers under 35 U.S.C. §13c. Under one method, an auditor receives an order for a quantity of pharmaceuticals, receives a report associated with the order containing sufficient information therein to perform an audit on the order, and compares the information found in the order with the information found in the associated report to make a status determination as to whether a buyer qualifies for an “own use” discount. Preferably a second report containing additional audit information is received as well. The auditor can also audit the order by comparing the order to this additional information. If these comparisons result in a determination that the buyer does in fact qualify for an “own use” discount, the auditor can then place the order with a pharmaceutical seller for a discounted price. Also disclosed is a pharmaceutical order auditing system that uses a computer to perform the above-described audit.
Owner:GOURLEY EWING B
Enhanced bioavailability of nutrients, pharmaceutical agents, and other bioactive substances through laser resonant homogenization or modification of molecular shape or crystalline form
InactiveUS20040230257A1Stimulating biological processMore benefitOrganic active ingredientsImpression capsDiseaseArginine
A method for improving the bioavailability of a bioactive substance includes subjecting the bioactive substance to laser radiation. The laser radiation modifies the bioactive substance to thereby modify reactions relating thereto in the body. The method enables reductions in inflammation associated with autoimmune diseases, modification of reaction by-products in the body, increased homogenization and flattening of molecular shape and improved methylation. The improved methylation can be utilized to reduce homocysteine blood levels, and to reduce anxiety, depression, paranoia, hostility, somatization (perception of bodily distress) and obsessive-compulsive symptoms. Enhanced nitric oxide generation from modified L-arginine can be used to reduce systolic and diastolic blood pressure, lower total and LDL cholesterol levels, and improve the ratio of total to HDL cholesterol. Increased depth of penetration of sparse constructive nodes of laser radiation may increase the range of photodynamic therapy applications and a wide range of in vitro and in vivo modifications of molecular shape and activity. Laser acoustic resonance can be utilized to increase the homogeneity of crystals, or favor the generation of novel or preferred crystalline forms.
Owner:OVOKAITYS TODD F
Intranasal administration of pharmaceutical agents for treatment of neurological diseases
Pharmaceutical formulations for treating neurological diseases are described, wherein the formulations comprise a pharmaceutically active agent-transport moiety complex. The formulations are suitable for administration via an intranasal route. Neurological diseases and conditions are associated with reduced brain insulin signaling (i.e., CNS insulin insensitivity), reduced dopaminergic signaling, reduced serotonergic signaling, reduced cholinergic signaling, or reduced GABAergic signaling, and include Alzheimer's disease, Parkinson's disease, epilepsy, neuropathic pain, fibromyalgia, post-herpetic neuralgia, insomnia, or anxiety. Neurological diseases also include cancers of the central nervous system (CNS).
Owner:WONG PATRICK SL
System and method for making personalized indvidual unit doses containing pharmaceutical actives
Systems and methods for making and delivering personalized, medically prescribed pharmaceuticals to an individual patient are described. Individual unit doses (IUDs) of medicine may be prepared specific to the individual in need of same, by using a system, which includes a networked control system in combination with manufacturing assemblies specific to the IUDs and delivering the medicine to the patient directly from the manufacturer.
Owner:AQUESTIVE THERAPEUTICS INC
Compositions to enhance the efficacy and safety of bio-pharmaceutical drugs
InactiveUS6593094B2Compounds screening/testingOrganic active ingredientsSide effectCost effectiveness
Owner:ENHANCED PHARMA
Purine derivatives and their pharmaceutical uses
Owner:GLAXO SMITHKLINE LLC
Topical personal care and pharmaceutical compositions and uses thereof
InactiveUS20120093748A1Less irritatingReduce stingingCosmetic preparationsBiocidePersonal careIrritation
Topical compositions are provided that have 0.5% or more of at least one personal care or pharmaceutical acid, and lightly- to moderately-crosslinked PVP, which is an effective thickener in the low pH systems. In preferred embodiments, the acid is a hydroxy acid and the composition used for personal care, or prescriptive or non-prescriptive medication indications for use on the skin, hair, scalp, foot, or lips. Also provided is the use of the topical compositions to deliver the acid(s) to the skin, hair, scalp, foot, or lips. Especially preferred is a use to reduce irritation and stinging compared to an equivalent compositions not having lightly- to moderately-crosslinked PVP.
Owner:ISP INVESTMENTS INC
Pharmaceutical uses of NBC1 N-cyano amide sulfide inhibitor S0859
InactiveCN109288828AEasy to refactorRefactoring delayAmide active ingredientsCardiovascular disorderLeft Ventricle RemodelingPharmaceutical care
The present invention relates to pharmaceutical uses of a Na<+>-coupled HCO3< > transporter (NBC1) N-cyano amide sulfide inhibitor S0859, and provides uses of a Na<+>-coupled HCO3< > transporter (NBC1) N-cyano amide sulfide inhibitor S0859 in preparation of heart failure treating drugs. According to the present invention, the results prove that the inhibitor S0859 can regulate the intracellular calcium ion homeostasis after myocardial infarction, improve ventricular remodeling, and inhibit intracellular calcium overload so as to inhibit ventricular remodeling, such that the invention can provide a new heart failure treating drug so as to effectively delay heart failure and ventricular remodeling caused by myocardial infarction.
Owner:NANFANG HOSPITAL OF SOUTHERN MEDICAL UNIV
Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)
InactiveUS20190262325A1Reduce contentReduce expressionOrganic active ingredientsDigestive systemFactor iiTG - Triglyceride
The present invention relates to the use of a pharmaceutical composition in the form of extended-release tablets containing Pirfenidone for treating NAFLD / NASH and advanced liver fibrosis by decreased serum cholesterol and triglycerides as well as reducing the content of hepatic fat accumulation, both in the form of macrosteatosis and microsteatosis. Additionally, its use as an agonist for PPARgamma (peroxisome proliferation receptor activated gamma), PPARalpha (peroxisome proliferation receptor activated alpha), LXR and CPT1, key molecules in the metabolism of fatty degradation and inflammation of the liver. In addition, another use is the induction of decreased expression of NFkB master gene, transcriptional inducer of hepatic inflammatory process factor. All of these events results in the reversal of NAFLD / NASH and advanced liver fibrosis.
Owner:EXCALIBUR PHARM INC
Method for screening and identifying pharmaceutical agents
InactiveUS7332272B1Evaluating effectFully characterizedMicrobiological testing/measurementBiological testingAnalytePrimary screening
The present invention describes the use of molecular expression profiles in the primary screening of compounds for pharmacological activity. In some embodiments, the methods of the invention comprise characterizing a profile of expression levels of a number of distinct biological molecules for two distinct sample types (A and B) that differ by some relevant parameter, in order to characterize the difference between the two types in terms of expression profile. Following this, one of the types (B) is treated with an analyte of unknown activity relative to the parameter by which the sample types differ. The expression profile of treated B is then measured and compared with the expression profiles of A and untreated B to ascertain whether the analyte has induced a shift in the profile of B to more closely or more distantly resemble the profile of A in some meaningful way.
Owner:GUNTHER ERIK
Method of reducing the risk of adverse cardiovascular (CV) events associated with the administration of pharmaceutical agents which favor CV events
Owner:HELLSTROM HAROLD RICHARD
System and method for providing real time control of pharmaceuticals
ActiveUS20140172447A1Sufficient inventory levelData processing applicationsDrug and medicationsUser inputTime control
Disclosed herein is a system for providing a user with remote real time access to pharmaceuticals, the system comprising a plurality of carts which accept cassettes that contain pharmaceuticals. The carts preferably contain a CPU which can communicate with a database. A remote CPU is also in electrical communication with the database and may be placed at a pharmacy. When a specific pharmaceutical is required for a specific patient, a user can electronically request a one time access code (OTAC) from the remote CPU. If the request is valid, an OTAC can be sent both electronically to the database in addition to being sent to the user. If the user inputs an OTAC that matches the one stored on the database, the cart is unlocked to provide access to the requested pharmaceutical. Pharmaceuticals that are currently found in the cart can be checked remotely by communicating with the database. A new cassette can then be stocked and sealed by a pharmacist, while another person can transmit the sealed cassette and replace the old cassette within the cart.
Owner:CAPSA SOLUTIONS
Power-supplying medical nursing combination cart
PendingCN107224371AEasy to replaceImprove work efficiencyBatteries circuit arrangementsElectric powerPatch panelLong-term care
The invention discloses a powered cart base for medical care combination, the top of the base is connected with a battery cabinet through fastening bolts, and both ends of one side of the battery cabinet are connected with a door of the battery cabinet through hinges. One side of the battery cabinet is provided with an opening, and the opening is adapted to the door of the battery cabinet, and the inner wall of the bottom of the battery cabinet is connected to equidistantly distributed limiting slide rail groups by fastening bolts. The present invention installs lockers and workbenches on the combined medical care cart, and combines the ordinary nursing cart with the carrying cart of nursing equipment. While classifying and storing medicines and nursing tools, it can also carry medical care through the installation bracket. The equipment is powered by rechargeable batteries for medical care equipment. Three rechargeable batteries and plug-in boards are installed inside the battery cabinet through the limit slide rail group. At the same time, the rechargeable battery is easy to replace, just push the rechargeable battery into the battery cabinet. It can provide stable and long-term power supply for nursing equipment.
Owner:湖南丹尼尔智能科技有限公司
Method For Determining Drug-Molecular Combinations That Modulate And Enhance The Therapeutic Safety And Efficacy Of Biological Or Pharmaceutical Drugs
ActiveUS20090012717A1Improve therapeutic safetyImprove efficacyBiological testingSpecial data processing applicationsSide effectCost effectiveness
A method that creates a new class of pharmaceutical combinations (specific ratio combinations) that offer an improved therapeutic profile with reduced side effects is provided. Safer, more cost-effective drugs for treating various diseases or medical conditions are created by combining receptor activating, inhibiting or modulating drugs in specific ratio combinations that optimize the therapeutic profiles for various pharmaceutical compositions. The method demonstrates how to combine biological or pharmaceutical molecules or drugs in order to create specific ratio combinations that are optimized to improve the overall safety and therapeutic efficacy of the individual molecules or drugs alone. These techniques create novel receptor-activating drugs that are anticipated to prove useful for future therapeutic treatments.
Owner:ENHANCED PHARMA
Anticoagulant pharmaceutical monitoring management method based on clinical data
ActiveCN111210890AImproving the Efficiency of Anticoagulant Pharmaceutical CareImprove the effect of anticoagulant therapyMedical data miningHealth-index calculationPatient needEmergency medicine
The invention discloses an anticoagulant pharmaceutical monitoring management method based on clinical data. The method is characterized by comprising the following steps: step 1, realizing clinical data acquisition and processing; step 2, realizing group entry evaluation of monitored patients; and step 3, realizing active monitoring and real-time early warning. Patients needing to be subjected toanticoagulation pharmaceutical monitoring can be automatically brought into pharmaceutical monitoring, and automatic, intelligent and active monitoring and real-time early warning are conducted on the monitored patients according to a monitoring early warning model. Therefore, the anticoagulation treatment effect is greatly improved, serious adverse events such as bleeding and stroke are reduced;meanwhile, the anticoagulation pharmacy monitoring work efficiency of clinical pharmacists is greatly improved.
Owner:成都木老仁康软件信息有限公司
Substituted aromatic compounds and pharmaceutical uses thereof
The present invention relates to substituted aromatic compounds of Formula I and their pharmaceutical uses. Particular aspects of the invention relate to the use of those compounds in the prevention and / or treatment of various diseases and conditions in subjects, including the prevention or treatment of (i) blood disorders, (ii) renal disorders, a nephropathies, or renal disorder complications; (iii) inflammatory-related diseases; and / or (iv) oxidative stress related disorders.
Owner:PROMETIC PHARMA SMT LTD
Out-of-hospital pharmaceutical monitoring system and method based on smart cloud platform
PendingCN111402975AMake up for lack of access to pharmaceutical careExtensive and convenient data collection channelsHealth-index calculationDrug and medicationsMonitoring systemTrend prediction
The invention discloses an out-of-hospital pharmaceutical monitoring system and method based on a smart cloud platform, belonging to the technical field of pharmaceutical monitoring. The system comprises an acquisition device for information of a monitored object and a smart cloud platform, wherein the acquisition device for the information of the monitored object is used for acquiring daily monitoring data of the monitored object outside a hospital; the smart cloud platform comprises receiving module for the information of the monitored object, a knowledge base module, a service governance and data distribution module, a data processing module, a data storage module, a data processing and trend prediction module and a pharmacist module. The invention provides the acquisition device for acquisition device for the information of the monitored object, and the smart cloud platform. The acquisition device for the information of the monitored object is an intelligent wristband, an intelligent medicine box, a monitor or the like, the monitored object can use the device for health information acquisition outside the hospital and for logging in the smart cloud platform to obtain pharmaceutical monitoring, so the defect that the monitored object cannot obtain pharmaceutical monitoring outside the hospital is overcome.
Owner:苏州艾隆信息技术有限公司
Fused ring compounds and use thereof
InactiveUS20110098297A1Superior glucokinase activating actionBiocideOrganic chemistryPharmaceutical careObesity
The present invention aims to provide a glucokinase activator useful as a pharmaceutical agent such as an agent for the prophylaxis or treatment of diabetes, obesity and the like. The present invention provides a glucokinase activator containing a compound represented by the formula (I): wherein each symbol is defined in the specification, or a salt thereof or a prodrug thereof.
Owner:TAKEDA PHARMA CO LTD
Aryl (Ethanoic) Propanoic Acid Ascorbyl Ester, Preparation Method Thereof And Medicament Containing The Same
InactiveUS20120115897A1Improve bioavailabilityImprove solubilityBiocideNervous disorderSolubilityAscorbigen
The present invention designs and synthesizes the ascorbyl ester derivatives of the aryl (ethanoic) propanoic acid non-steroidal anti-inflammatory medicaments, such as ibuprofen, ketoprofen and naproxen, and addition salt of the derivatives with pharmaceutical acid or pharmaceutical alkaline. The non-steroidal anti-inflammatory medicament which takes the ibuprofen as the representative is a common antipyretic analgesic medicament. The invention has remarkable antipyretic and analgesic effects and good safety except for anti-inflammatory effect, thus being not only suitable for adults, but also suitable for the elderly people, infants and children. The aryl (ethanoic) propanoic acid ascorbyl ester can be converted into ascorbyl ester derivatives and the addition salts of the derivatives with pharmaceutical acid or pharmaceutical alkaline, which can improve the water solubility thereof, facilitate intravenously administration, reduce the onset time, improve the bioavailability, reduce the stimulation effect to gastrointestinal tract, and enhance the penetrating capacity to hemato encephalic barrier, and can be used as a novel medicament to be applied for antiphlogistic, antipyresis, analgesia, treatment of arthritis, dysmenorrheal, multiple sclerosis, pneumonia cystic fibrosis and patent ductus arteriosus of premature infants, and prevention and treatment of cerebral apoplexy, hypoxic-ischemic brain damage, senile dementia and certain cancers.
Owner:WUXI HONGRUI BIOMEDICAL TECH CO LTD +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com